Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Carcinoid syndrome is most common in people with a small bowel NET which has spread to the liver. It can also happen in people with lung and pancreatic NETs. But this is less common. The skin of your ...

accounting for about 95% of pancreatic cancers Pancreatic neuroendocrine tumor: Cancer of the endocrine cells. Treatment for pancreatic cancer involves surgery to remove part or all of the ...

Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine ...

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

Exelixis (EXEL) wins FDA approval for Cabometyx for advanced pancreatic and extra pancreatic neuroendocrine tumors in ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...